Literature DB >> 2539371

Differential patterns of intracellular metabolism of 2',3'-didehydro-2',3'-dideoxythymidine and 3'-azido-2',3'-dideoxythymidine, two potent anti-human immunodeficiency virus compounds.

J Balzarini1, P Herdewijn, E De Clercq.   

Abstract

3'-Azido-2',3'-dideoxythymidine (AZT) and 2',3'-didehydro-2',3'-dideoxythymidine (D4T) are potent and selective inhibitors of human immunodeficiency virus replication in MT-4 and ATH8 cells. They are also inhibitory to the replication of murine retroviruses, i.e. Moloney murine sarcoma virus-induced transformation of C3H cells. In MT-4 cells AZT is readily phosphorylated to its 5'-monophosphate, while the 5'-di- and 5'-triphosphates are generated to a 200-600-fold lower extent than the 5'-monophosphate. D4T is phosphorylated in MT-4 cells to its 5'-monophosphate at a 300-600-fold lower extent than AZT. The phosphorylation of AZT in the thymidine kinase-deficient cell line (Raji/TK-) is severely depressed, while D4T phosphorylation is only slightly diminished in Raji/TK- as compared to Raji/0 cells. D4T has a 10-fold lower affinity for phosphorylation by crude MT-4 cell extracts than AZT (Km, 142 and 14 microM, respectively), and the Vmax for phosphorylation of D4T is only 5% that of AZT. D4T is phosphorylated by MT-4 cell extracts about 180-fold less efficiently than AZT (Vmax/Km, 0.06 for D4T, as compared to 11 for AZT), and this is consistent with the differences found in the amounts of phosphorylated products of D4T and AZT formed in intact MT-4 cells. The 5'-triphosphates of AZT and D4T are equipotent in their inhibitory effects on the reverse transcriptases from human immunodeficiency virus and Moloney murine leukemia virus.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2539371

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  52 in total

1.  Stampidine is a potent inhibitor of Zidovudine- and nucleoside analog reverse transcriptase inhibitor-resistant primary clinical human immunodeficiency virus type 1 isolates with thymidine analog mutations.

Authors:  Fatih M Uckun; Sharon Pendergrass; T K Venkatachalam; Sanjive Qazi; Douglas Richman
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

Review 2.  Stavudine once daily.

Authors:  Susan M Cheer; Karen L Goa
Journal:  Drugs       Date:  2002       Impact factor: 9.546

3.  Mechanism of anti-HIV action of masked alaninyl d4T-MP derivatives.

Authors:  J Balzarini; A Karlsson; S Aquaro; C F Perno; D Cahard; L Naesens; E De Clercq; C McGuigan
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

4.  Determinants of individual variation in intracellular accumulation of anti-HIV nucleoside analog metabolites.

Authors:  Elijah Paintsil; Ginger E Dutschman; Rong Hu; Susan P Grill; Chuan-Jen Wang; Wing Lam; Fang-Yong Li; Musie Ghebremichael; Veronika Northrup; Yung-Chi Cheng
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

Review 5.  Stavudine: an update of its use in the treatment of HIV infection.

Authors:  M Hurst; S Noble
Journal:  Drugs       Date:  1999-11       Impact factor: 9.546

Review 6.  Clinical pharmacokinetics of stavudine.

Authors:  K Z Rana; M N Dudley
Journal:  Clin Pharmacokinet       Date:  1997-10       Impact factor: 6.447

Review 7.  Metabolism and mechanism of antiretroviral action of purine and pyrimidine derivatives.

Authors:  J Balzarini
Journal:  Pharm World Sci       Date:  1994-04-15

8.  Selective inhibition of porcine endogenous retrovirus replication in human cells by acyclic nucleoside phosphonates.

Authors:  Minyi Shi; Xin Wang; Erik De Clercq; Sonshin Takao; Masanori Baba
Journal:  Antimicrob Agents Chemother       Date:  2007-04-30       Impact factor: 5.191

9.  S-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1.

Authors:  T Fujiwara; A Sato; M el-Farrash; S Miki; K Abe; Y Isaka; M Kodama; Y Wu; L B Chen; H Harada; H Sugimoto; M Hatanaka; Y Hinuma
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

10.  Synthesis, characterization, and in vitro assay of folic acid conjugates of 3'-azido-3'-deoxythymidine (AZT): toward targeted AZT based anticancer therapeutics.

Authors:  Anthony R Vortherms; Robert P Doyle; Dayuan Gao; Olivia Debrah; Patrick J Sinko
Journal:  Nucleosides Nucleotides Nucleic Acids       Date:  2008-02       Impact factor: 1.381

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.